MCCORMICK FRANK

Director Frank McCormick sells 198,359 shares for $13.2M at avg $66.58; holds 679,979 shares post-transaction

Frank McCormick, a director at BridgeBio Pharma, executed 5 separate sales totaling 198,359 shares for $13,206,527.69 on 2025-10-29, reducing his holdings by 22.6% to 679,979 shares. The transactions occurred at prices ranging from $65.48 to $69.24, with a blended average of $66.58—near the 52-week high of $66.62. At the current price of $62.64, the stock has declined 6.0% from its peak. McCormick's cross-ticker track record shows 3 prior sells with an average 90-day return of -6.8% and a 50% well-timed rate; his same-ticker history at BBIO presents mixed timing—1 of 2 prior sales was well-timed at the 90-day mark. The company remains unprofitable (net income of -$184.9M in the latest full fiscal year) despite explosive revenue growth of 2285.3% year-over-year, creating a backdrop of uncertainty that may contextualize a substantial reduction in director-level holdings.

Director Frank McCormick sold 74,000 shares (74.0K) of BBIO at $53.16; stock at $54.29, near 52-week high (+0.0%). Up 35.4% in 90 days.

Director McCormick sold 74,000 shares at $53.16 on 2025-09-05, reducing his holdings by -47.1% to 83.3K shares, generating $3,933,544.00 in proceeds. The sale occurred near the company's 52-week high ($54.29 current price, +0.0% from peak), following a strong 90-day rally of 35.4%. Across his cross-ticker track record, McCormick's prior 2 sales showed an average 90-day return of -30.1% and a 100.00% well-timed rate, but at BBIO specifically, his timing has been more mixed: his 2023-12-26 sale was well-timed (post-sale decline of -30.1%), while his 2025-06-24 sale saw a +3.2% 30-day gain. BridgeBio remains unprofitable (net income $-183.8M on $110.6M quarterly revenue), presenting a fundamental offset to the recent price momentum.

Director Frank McCormick sold 100,000 shares (100.0K shares) of BBIO at $44.23 on 2025-06-24, retaining 879,979 shares (880.0K shares).

Director Frank McCormick sold 100,000 shares at $44.23, reducing his position by 10.2% from 979,979 shares to 879,979 shares. The stock has since risen to $45.12 and is at its 52-week high, with strong recent momentum (+36.3% over 30 days and +28.5% over 90 days). McCormick's cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 100.00%, and his prior BBIO sale on 2023-12-26 also showed a 90-day well-timed outcome (-30.1% return). Notably, this sale occurs while the company remains unprofitable (net income of $-169,608,000.00) despite exceptional annual revenue growth of +2285.3%, suggesting the stock's recent strength may not reflect underlying profitability trajectory. The timing relative to price momentum and fundamental challenges warrants observation.